Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients

Abstract

Volume criteria (especially ellipsoids) classify a higher number of patients as imatinib-responders than RECIST. Volume discriminates size changes better than diameter in GIST and constitutes a feasible and robust method to evaluate response and predict patient benefit.